Bayer defends patent rights on rivaroxaban (Xarelto™) in Latvia

Bayer is actively defending its patent for rivaroxaban (Xarelto™) in Latvia in response to challenges from several generic pharmaceutical companies. The patent revocation proceedings in Latvia are part of broader legal actions spanning multiple European jurisdictions.

Rivaroxaban is the active pharmaceutical ingredient in the anticoagulant Xarelto™, an acclaimed blood thinner used to treat and prevent blood clots related to certain heart and blood vessel conditions.

In Latvia, Bayer’s patent rights are represented by COBALT.